Fidia Introduces Hymovis®, a Next-Generation Hyaluronan, at the AAOS Annual Meeting in Orlando

Hymovis®, which is being launched in the U.S, is a highly viscoelastic hydrogel (HYADD®4) engineered using a proprietary process that increases lubrication and shock absorption properties

PARSIPPANY, N.J., February 25, 2016 – Fidia Farmaceutici S.p.A., a world leader in the research, development and manufacturing of hyaluronic acid (HA)-based products, and its wholly owned subsidiary, Fidia Pharma USA Inc., will introduce Hymovis® (high molecular weight viscoelastic hyaluronan) at the Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) in Orlando, March 1-5, 2016.

Hymovis® is a next-generation of HA-based intra-articular (IA) therapy indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy or simple analgesics. The product has a shorter treatment cycle of only two intra-articular injections as compared to many other IA HA viscosupplement regimens to provide pain relief for the patient.

For more information, please visit Fidia Pharma USA Inc. at the AAOS Annual Meeting at Booth 2003.


Find out more about Fidia’s product portfolio:

Go to the website


Fidia Farmaceutici has a specific module dedicated to Pharmaco-Vigilance in order to promptly reporting of suspected adverse reactions. If you suspect that you have had an adverse reaction while taking one of our products or you have found defects

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint care
- ophthalmology
- active wound care
- neuroscience
- aesthetic medicine